A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFN-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, or Fallopian Tube Carcinoma Failing Ineligible for First-Line Therapy (OCR 09-01)

Trial Profile

A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFN-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, or Fallopian Tube Carcinoma Failing Ineligible for First-Line Therapy (OCR 09-01)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2013

At a glance

  • Drugs Denileukin diftitox (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top